HIGHLIGHTS
- who: Huiling Wang from the University Hospital Erlangen, Germany have published the article: Immune-based combination therapy for esophageal cancer, in the Journal: (JOURNAL) of May/12,/2020
- what: This trial demonstrated encouraging anti-tumor activity as a first-line treatment and acceptable safety. The data from this trial have not been reported hitherto. The study showed a significant improvement in median PFS (mPFS), documenting the shortterm efficacy of mPFS, objective response rate (ORR), and the long-term effect of median OS (mOS). The OS difference was insignificant (HR: 0.90, 95% CI: 0.75 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.